Moderna Stock Falls as Study of Influenza Vaccine Has Mixed Results

Moderna


the biotechnology company, was falling on Friday after a study of its new flu vaccine had mixed results.

Moderna (ticker: MRNA) said on Thursday that its experimental RNA-based influenza vaccine generated a strong immune response, but that it wasn’t proven that it was at least as effective as already-approved vaccines.